Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer
09 mars 2021 07h10 HE
|
Apollomics, Inc.
- Fibrogen veteran brings global R&D expertise to Management Team - - Merck KGaA Executive Sophie (Zhengjie) Sun named Senior Vice President, Corporate Development bringing partnership, strategy...
Apollomics, Inc. Announces Successful Enrollment of First Patient Into Phase 1 Clinical Trial of APL-106 (Uproleselan Injection) in China
04 mars 2021 07h10 HE
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, China, March 04, 2021 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono-...
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
12 févr. 2021 07h10 HE
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, China, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater China
10 févr. 2021 07h10 HE
|
Apollomics, Inc.
FOSTER CITY, Calif., HANGZHOU, China and HOUSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors
09 févr. 2021 07h10 HE
|
Apollomics, Inc.; Edison Oncology
- Apollomics licenses worldwide rights (ex-China, Hong Kong and Taiwan) to develop and commercialize EO1001 - - EO1001 is an irreversible, pan-erbB inhibitor of EGFR (ErbB1), HER2 (ErbB2) and...
APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia
07 janv. 2021 07h10 HE
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China and GAITHERSBURG, Md., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development...
Apollomics, Inc. Receives China Investigational New Drug Approval for APL-102 to Initiate a Phase 1 Study
12 nov. 2020 07h10 HE
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of new tumor-targeting...
Apollomics, Inc. Closes $124 Million Series C Financing
06 nov. 2020 07h10 HE
|
Apollomics, Inc.
- Financing led by Ping An Capital - - Phase 2 SPARTA Trial for APL-101 Now Enrolling - - Phase 3 Clinical Trial to begin in China for APL-106 (Uproleselan) - FOSTER CITY, Calif. and HANGZHOU,...
Apollomics, Inc. Receives China Investigational New Drug Approval for APL-106 to Initiate a Phase 3 Bridging Study in Acute Myeloid Leukemia
27 sept. 2020 20h05 HE
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China, Sept. 27, 2020 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics, Inc. 宣佈啟動針對 c-MET 抑製劑 APL-101 的 SPARTA 第 2 期臨床試驗
21 mai 2020 21h37 HE
|
Apollomics, Inc.
- 試驗將評估廣泛腫瘤類型的各種 MET 失調 - - 專於具有導致 MET 外顯子 14 跳讀的突變非小細胞肺癌，以及具有擴增性和 MET 融合的腫瘤，包括多形膠質母細胞瘤 - 加州福斯特市和中國杭州, May 22, 2020 (GLOBE NEWSWIRE) -- Apollomics, Inc. 是致力發現和開發腫瘤學單一療法和聯合療法的創新生物製藥公司，今天宣佈啟動...